评估降脂药物靶点对全病程糖尿病视网膜病变的作用
本研究采用两样本孟德尔随机化和药物靶点孟德尔随机化方法,评估脂质性状及降脂药物靶点与全病程糖尿病视网膜病变(包括背景期DR、重度非增殖期DR和增殖期DR)的因果关系。结果显示脂质性状与全病程DR无显著因果关系,但过氧化物酶体增殖物激活受体γ(PPARG)增强与背景期DR(OR=0.12,p=0.005)和增殖期DR(OR=0.25,p=0.006)风险降低相关。中介分析显示降低空腹胰岛素(p=0.015)和HbA1c(p=0.005)水平介导了PPARG与全病程DR之间的大部分关联。
要点
- 脂质性状与全病程DR无显著因果关系。
- PPARG增强与背景期DR风险降低相关(OR=0.12,p=0.005)。
- PPARG增强与增殖期DR风险降低相关(OR=0.25,p=0.006)。
核心结论
- PPARG可能是全病程DR有前景的药物靶点,其激活可降低全病程DR风险,尤其是背景期DR和增殖期DR。
- PPARG激动剂保护全病程DR的机制可能依赖于降糖效应。
研究设计与样本
- 研究采用两样本孟德尔随机化和药物靶点孟德尔随机化方法,评估脂质性状和降脂药物靶点对全病程DR的因果效应。
- 脂质性状相关遗传变异和降脂药物蛋白靶点编码基因取自Global Lipids Genetics Consortium和UK Biobank。
- 全病程DR的汇总水平数据取自FinnGen。
主要发现
- 脂质性状与全病程DR之间未发现显著因果关系。
- 药物靶点孟德尔随机化分析中,PPARG增强与背景期DR风险降低相关(OR=0.12,p=0.005)。
- PPARG增强与增殖期DR风险降低相关(OR=0.25,p=0.006)。
- 中介孟德尔随机化分析显示,降低空腹胰岛素水平(p=0.015)和HbA1c水平(p=0.005)介导了PPARG与全病程DR之间的大部分关联。
关键数值与推荐
- PPARG增强与背景期DR的OR=0.12(p=0.005)。
- PPARG增强与增殖期DR的OR=0.25(p=0.006)。
- 降低空腹胰岛素水平中介效应的p=0.015。
- 降低HbA1c水平中介效应的p=0.005。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implementing lipid control in patients with diabetes is regarded as a potential strategy for halting the advancement of diabetic retinopathy (DR). This study seeks to use Mendelian randomisation (MR) to assess the causal relationship between lipid traits and lipid-lowering drug targets and full-course DR (background DR, severe non-proliferative DR (NPDR) and proliferative DR (PDR)). METHODS: A two-sample MR and drug target MR to decipher the causal effects of lipid traits and lipid-lowering drug targets on full-course DR, including background DR, severe NPDR and PDR, was conducted in the study. Genetic variants associated with lipid traits and genes encoding the protein targets of lipid-lowering drugs were extracted from the Global Lipids Genetics Consortium and UK Biobank. Summary-level data of full-course DR are obtained from FinnGen. RESULTS: No significant causal relationship was found between lipid traits and full-course DR. However, in drug target MR analysis, peroxisome proliferator-activated receptor gamma (PPARG) enhancement was associated with lower risks of background DR (OR=0.12, p=0.005) and PDR (OR=0.25, p=0.006). Additionally, mediation MR analysis showed that lowering fasting insulin (p=0.015) and HbA1c (p=0.005) levels mediated most of the association between PPARG and full-course DR. CONCLUSIONS: This study reveals PPARG may be a promising drug target for full-course DR. The activation of PPARG could reduce the risk of full-course DR, especially background DR and PDR. The mechanism of the PPARG agonists' protection of full-course DR may be dependent on the glucose-lowering effect.
引用
- Cao J, Su T, Chen S, et al. Evaluating lipid-lowering drug targets for full-course diabetic retinopathy. Br J Ophthalmol. 2025. PMID: 39900481. doi:10.1136/bjo-2024-325771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。